Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study

Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident. To define the association between negative surveillance PNBs and risk of reclassification on AS. All men were enrolled in the Canary Prostate Activ...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2018-05, Vol.73 (5), p.706-712
Main Authors: Kearns, James T., Faino, Anna V., Newcomb, Lisa F., Brooks, James D., Carroll, Peter R., Dash, Atreya, Ellis, William J., Fabrizio, Michael, Gleave, Martin E., Morgan, Todd M., Nelson, Peter S., Thompson, Ian M., Wagner, Andrew A., Zheng, Yingye, Lin, Daniel W.
Format: Article
Language:English
Subjects:
Active surveillance
Aged
Asymptomatic Diseases
Biomarkers, Tumor - blood
Biopsy, Needle
Cohort Studies
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Neoplasm Grading - methods
Neoplasm Invasiveness - pathology
Prognosis
Proportional Hazards Models
Prostate biopsy
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - classification
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Retrospective Studies
Time Factors
Watchful Waiting - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident. To define the association between negative surveillance PNBs and risk of reclassification on AS. All men were enrolled in the Canary Prostate Active Surveillance Study (PASS) between 2008 and 2016. Men were included if they had Gleason ≤3+4 prostate cancer and
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2018.01.016